Personalis, Inc. (PSNL)

Market Cap	722.87M +91.0%
Revenue (ttm)	69.10M -21.0%
Net Income	-73.88M
EPS	-0.88
Shares Out	88.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	540,819
Open	8.17
Previous Close	8.28
Day's Range	7.83 - 8.24
52-Week Range	2.83 - 11.50
Beta	2.02
Analysts	Strong Buy
Price Target	11.33 (+39.19%)
Earnings Date	Feb 26, 2026

About PSNL

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample....

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: PSNL
• Website: https://www.personalis.com

Financial Performance

In 2024, Personalis's revenue was $84.61 million, an increase of 15.15% compared to the previous year's $73.48 million. Losses were -$81.28 million, -24.94% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price target is $11.33, which is an increase of 39.19% from the latest price.

Price Target

$11.33

(39.19% upside)

Analyst Consensus: Strong Buy